Reply to: Forget personalized medicine and focus on abating disease activity

Annals of the Rheumatic Diseases

Volumn 72, Issue 5, 2013, Pages

  Wilke, William Samuel ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD19 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 6; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR;

DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; LETTER; MONOTHERAPY; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY;

EID: 84875966494     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203297     Document Type: Letter

References (24)

1. Smolen JS, Aletaha D. Forget personalized medicine and focus on abating disease activity. Ann Rheum Dis 2013;72:3-6.
2. Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 2012;71:225-30.
3. Guyot P, Taylor PC, Christensen R, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom. J Rheumatol 2012;39:1198-206.
4. Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis; 52-week results from the JESMR study. J Rheumatol 2011;38:1585-92.
5. Ostergaard M, Emery P, Conagan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone. A magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712-22.
6. Barton JL, Imboden J, Graf J, et al. Patient-physician discordance in assessments of global severity in rheumatoid arthritis. Arthritis Care Res 2010;62:857-64.
7. Nicolau G, Yogui MM, Vallochi TL, et al. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004;31:1293-6. (Pubitemid 38879191)
8. Studenic P, Radner H, Smolen JS, et al. Discrepancies between patients and physicians in the perception of rheumatoid arthritis disease activity. Arthritis Rheum 2012;64:2814-23.
9. Leeb BF, Haindl PM, Maktari A, et al. Disease Activity Score-28 values differ considerably depending on patient's pain perception and sex. J Rheumatol 2007;34:2382-7. (Pubitemid 350230659)
10. Masri KR, Shaver TS, Shahouri SH, et al. Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol 2012;39:1139-45.
11. Lee YC, Cui J, Lu B, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011;13:R83-92.
12. Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis facto-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis; a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011;71:225-30.
13. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNF-alpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009;61:107-17.
14. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004;31:695-700. (Pubitemid 38451254)
15. Lal P, Su Z, Holweg CT, et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum 2011;63:3681-91.
16. Karimifar M, Salesi M, Faraizadegan Z. The association of anti-CCP-1 antibodies with disease activity score 28 (DAS28) in rheumatoid arthritis. Adv Biomed Res 2012;1:30.
17. Padyukov L, Seielstadt M, Ong RTH, et al. A genome-wide association study suggests contrasting associations I ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011;70:259-65.
18. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to ant-tumor necrosis factor therapy. Results of a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
19. Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anti-citrullinated peptide antibody serotypes on rituximab clinical response: a meta-analysis. Ann Rheum Dis Published Online First: 11 June 2012. doi:10.1136/annrhemdis-2011-201117
20. You S, Cho C-S, Lee I, et al. A systems approach to rheumatoid arthritis. PLoS ONE 2012;7:e51508. doi:10.1371/journal.pone.0051508
21. Ortea I, Roschititzki B, Ovalles JG, et al. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics 2012;77:372-82.
22. Bakker MF, Cavet G, Jacobs JWG, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71:1692-7.
23. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multimarker test to assess rheumatoid arthritis. Arthritis Care Res 2012;64:1794-803.
24. van der Helm-van Mil AHM, Knevel R, Cavet G, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology Published Online First: 3 Jan 2013. doi:10.1093/rheumatology/kes378 e8 Ann